VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ARDX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ARDXArdelyx, Inc.
$5.38$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

ARDX logoArdelyx, Inc.(ARDX)Earnings, Financials & Key Ratios

ARDX•NASDAQ
$5.38
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCommercial Specialty Pharma
AboutArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Show more
  • Revenue$407M+22.1%
  • EBITDA-$38M-46.5%
  • Net Income-$62M-57.4%
  • EPS (Diluted)-0.26-52.9%
  • Gross Margin89.54%+5.5%
  • EBITDA Margin-9.31%-20.0%
  • Operating Margin-10.06%-20.1%
  • Net Margin-15.12%-28.9%
  • ROE-36.21%-57.3%

ARDX Price & Volume

Ardelyx, Inc. (ARDX) stock price & volume — 10-year historical chart

Loading chart...

Commercial Scaling Costs Threaten Long-term Solvency Outlook

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Strained
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Regulatory reimbursement uncertainty

Key Thesis Takeaways

  • Ardelyx faces a challenging path to profitability as aggressive SG&A spending, which reached $102.3 million in 2026Q1, continues to outpace revenue growth and erode the company's equity base.
  • While the firm maintains high gross margins exceeding 94%, the reliance on external debt—now totaling $208.3 million—to fund commercialization efforts creates significant financial vulnerability.
  • Investors should monitor the company's ability to achieve sustainable cash flow, as the current burn rate and $31.2 million cash position suggest a high probability of future dilutive financing.

Verdict Logic

the company's precarious liquidity position, highlighted by a cash balance of only $31.2 million against a quarterly cash burn of $32.3 million, warrants extreme caution regarding potential equity dilution.

ARDX Growth Metrics

Ardelyx, Inc. (ARDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years32.72%
5 Years121.9%
3 Years98.4%
TTM18.24%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-7.99%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-4.77%

Return on Capital

10 Years-48.82%
5 Years-45.14%
3 Years-17.97%
Last Year-10.63%

ARDX Recent Earnings

Ardelyx, Inc. (ARDX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 30, 2026
Metric
Actual
Est
EPS
$0.15-15.4%
$0.13
Rev
$94M+1.8%
$93M
Q1 2026
Feb 19, 2026
Metric
Actual
Est
EPS
$0.02+0.0%
$0.02
Rev
$125M+6.1%
$118M
Q4 2025
Oct 30, 2025
Metric
Actual
Est
EPS
$0.00+93.3%
$0.06
Rev
$110M-7.3%
$119M
Q3 2025
Aug 4, 2025
Metric
Actual
Est
EPS
$0.08+38.5%
$0.13
Rev
$98M+3.2%
$95M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 30, 2026
$0.15vs $0.13-15.4%
$94Mvs $93M+1.8%
Q1 2026Feb 19, 2026
$0.02vs $0.02+0.0%
$125Mvs $118M+6.1%
Q4 2025Oct 30, 2025
$0.00vs $0.06+93.3%
$110Mvs $119M-7.3%
Q3 2025Aug 4, 2025
$0.08vs $0.13+38.5%
$98Mvs $95M+3.2%
Based on last 12 quarters of dataView full earnings history →

Latest ARDX News

Recent stock market news and headlines for Ardelyx, Inc. (ARDX)

The Motley Fool·Jun 23, 2026
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction

According to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Stock shares on June 18, 2026, generating a transaction value of $490,000. The sale represented 17.8% of Williams's direct Common Stock holdings, reducing her Common Stock position to 378,195 shares (direct) post-transaction.

Peers Comparison

Key metrics vs top competitors for Ardelyx, Inc. (ARDX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ARDX logoARDXArdelyx, Inc.Current
$5.38$1.32B-20.6922.09%-15.12%-36.21%—
CYCN logoCYCNCyclerion Therapeutics, Inc.
$3.48$15.07M-3.193.7%-264.73%-62.1%—
CHRS logoCHRSCoherus Oncology, Inc.
$1.67$204.42M-1.15-84.2%-323.49%-174.71%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$323.95$9.36B-24.03-100%—-43.02%—
INVA logoINVAInnoviva, Inc.
$22.25$1.64B6.7418.52%118.91%47.59%—
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$47.41$2.73B-69.728.63%-3.74%-2.73%—

Compare ARDX vs Peers

Ardelyx, Inc. (ARDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CYCN

Most directly comparable listed peer for ARDX.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ARDX against a more recognizable public peer.

Peer Set

Compare Top 5

vs CYCN, CHRS, PRAX, INVA

ARDX SEC Filings & Documents

Ardelyx, Inc. (ARDX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 30, 2026·SEC

Material company update

Feb 19, 2026·SEC

Material company update

Jan 8, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 19, 2026·SEC

FY 2025

Feb 20, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 30, 2025·SEC

FY 2025

Aug 4, 2025·SEC

Get notified when ARDX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ARDX Frequently Asked Questions

Ardelyx, Inc. (ARDX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Ardelyx, Inc.'s revenue?

Ardelyx, Inc. (ARDX) reported $427.7M in revenue for fiscal year 2025. This represents a 7805% increase from $5.4M in 2012.

How fast is Ardelyx, Inc. growing?

Ardelyx, Inc. (ARDX) grew revenue by 22.1% over the past year. This is strong growth.

Is ARDX profitable?

Ardelyx, Inc. (ARDX) reported a net loss of $58.1M for fiscal year 2025.

Dividend & Returns
What is ARDX's return on equity?

Ardelyx, Inc. (ARDX) has a return on equity (ROE) of -36.2%. Negative ROE indicates the company is unprofitable.

What is Ardelyx, Inc.'s free cash flow?

Ardelyx, Inc. (ARDX) had negative free cash flow of $37.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ARDX back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →